Skip to main content
. 2013 Aug 30;288(41):29680–29691. doi: 10.1074/jbc.M113.495069

FIGURE 3.

FIGURE 3.

MLN4924 sensitizes ovarian cancer cells to chemotherapeutic drug treatment. A, cell viability after treatment with varying concentrations of chemotherapy drugs. B, MLN4924 (0.05 μm) treatment was combined with agents used for the clinical management of ovarian cancer. A2780, OV2008, and mOSE cells were seeded in 96-well plates in triplicate and treated with MLN4924 and the indicated therapeutic drugs for 96 h, followed by MTT assay. For A2780 and OV2008 cells, drug concentrations were: bleomycin (BLM), 20 μg/ml; doxorubicin (DOX), 0.5 μg/ml; and etoposide (VP-16), 5 μg/ml. For mOSE cells, drug concentrations were: bleomycin (20 μg/ml), doxorubicin (0.1 μg/ml), and etoposide (1 μg/ml). C, cell viability of MLN4924-treated ES-2 ovarian cancer cells, with or without Roc1/2 RNAi depletion.